EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Molecular Insights into Central Core Disease: Proteomic Signatures and Potential Therapeutic Biomarkers in RYR1 I4895T Mice

Lorenza Vantaggiato iD, Enxhi Shaba iD, Federica Fiore iD, Daniela Rossi iD, Vincenzo Sorrentino iD, Luca Bini iD, Claudia Landi iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262311451 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Lorenza Vantaggiato und 6 weiteren Autor:innen. Beteiligte Einrichtung: Functional Proteomics Lab., Department of Life Sciences, University of Siena, 53100 Siena, Italy. Hauptthemen laut MEDLINE: Ryanodine Receptor Calcium Release Channel, Proteomics, Myopathy, Central Core, Proteome. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union-Next Generation EU in the framework of the mRNA National Center for Gene Therapy and Drugs PNRR-M4C2-1.4 CN00000041, Italian Ministry of Education, Universities and Research (MUR) within the Italian PNRR, Tuscany Health Ecosystem.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Central Core Disease (CCD) is a congenital myopathy predominantly caused by mutations in the gene encoding ryanodine receptor type-1 (RYR1), the intracellular Ca2+ release channel embedded in the skeletal muscle sarcoplasmic reticulum membrane. The I4898T mutation represents one of the most common RYR1 mutations associated with CCD. Unfortunately, there are no approved therapies for CCD or for other myopathies caused by mutations in this gene. This study aims to perform a top-down differential proteomic analysis on soleus muscle samples from wild-type mice (WT) and heterozygous knock-in mice carrying the I4895T (IT) mutation in RyR1, to investigate the pathogenic mechanisms and molecular pathways involved in this myopathy and to shed light on new potential biomarkers useful for future therapies. Proteomic analysis revealed 50 dysregulated protein species, and multivariate analysis showed that IT mice exhibit a distinct proteomic signature compared to WT mice, characterized by alterations in proteins associated with contractile and structural dysfunction, metabolism, and stress response. In particular, a significant increase in myosin fragments was observed in IT mice, likely due to muscle breakdown. In contrast, myotilin was downregulated, suggesting a weakening of the muscle cytoskeletal structure. There was a notable downregulation of proteins involved in glycolysis and the TCA cycle; conversely, there was an increase in proteins related to anaerobic glycolysis, suggesting a shift from aerobic to anaerobic glycolysis. Furthermore, proteins involved in fatty acid beta-oxidation and oxidative phosphorylation were also found to be upregulated in IT mice, indicating an attempt by the muscle to maximize energy production. Finally, we found a significant decrease in PGC1α, which could serve as potential therapy target and biomarker in CCD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ryanodine Receptor Calcium Release ChannelProteomicsMyopathy, Central CoreProteomeAnimalsMiceBiomarkersMuscle, SkeletalMutationDisease Models, Animal

Stichwörter der Autor:innen

Central Core DiseasePGC1αRYR1glycolysisoxidative phosphorylationoxidative stress

Substanzen

Ryanodine Receptor Calcium Release ChannelBiomarkersryanodine receptor 1, mouseProteome

Autor:innen und Institutionen

  • Functional Proteomics Lab., Department of Life Sciences, University of Siena, 53100 Siena, Italy.
  • Department of Molecular and Developmental Medicine, University of Siena, 53100 Siena, Italy.
  • Program of Molecular Diagnosis of Rare Genetic Diseases, Azienda Ospedaliera Universitaria Senese, 53100 Siena, Italy.

ORCID-Profile: Lorenza Vantaggiato, Enxhi Shaba, Federica Fiore, Daniela Rossi, Vincenzo Sorrentino, Luca Bini, Claudia Landi

Förderung

  • European Union-Next Generation EU in the framework of the mRNA National Center for Gene Therapy and Drugs PNRR-M4C2-1.4 CN00000041
  • Italian Ministry of Education, Universities and Research (MUR) within the Italian PNRR, Tuscany Health Ecosystem

Zitieren

APA

Vantaggiato, L., Shaba, E., Fiore, F., Rossi, D., Sorrentino, V., Bini, L., & Landi, C. (2025). Molecular Insights into Central Core Disease: Proteomic Signatures and Potential Therapeutic Biomarkers in RYR1 I4895T Mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262311451

Vancouver

Vantaggiato L, Shaba E, Fiore F, Rossi D, Sorrentino V, Bini L, et al. Molecular Insights into Central Core Disease: Proteomic Signatures and Potential Therapeutic Biomarkers in RYR1 I4895T Mice. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262311451

BibTeX
@article{Vantaggiato2025,
  author = {Vantaggiato, Lorenza and Shaba, Enxhi and Fiore, Federica and Rossi, Daniela and Sorrentino, Vincenzo and Bini, Luca and Landi, Claudia},
  title = {Molecular Insights into Central Core Disease: Proteomic Signatures and Potential Therapeutic Biomarkers in RYR1 I4895T Mice},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262311451}
}
Kostenlos starten →